The decline in physical activity among adults with obesity who are undergoing weight loss treatments with GLP-1 receptor agonists is a cause for concern, according to a recent study presented at the Endocrine Society's annual meeting. This finding highlights the importance of incorporating physical activity into the treatment plan for these individuals, as it is crucial for preserving muscle mass and overall health.
The study, led by Dr. Sajana Maharjan, analyzed data from the National Institutes of Health's All of Us Research Program, linking participants' electronic health records with their Fitbit activity data. Among 1,950 adults with obesity who started a GLP-1 medication, 753 individuals with sufficient wearable-device data were studied. The cohort was predominantly female, with an average age of 52.7 years.
The results revealed a significant decrease in physical activity after starting GLP-1 treatment. Daily steps dropped from 5,047 to 4,487, and moderate-to-vigorous physical activity (MVPA) minutes fell from 28 to 22 per day. Interestingly, the largest declines were observed in men and individuals with joint or muscle pain, suggesting that these groups may be more susceptible to the negative effects of reduced physical activity.
Dr. Maharjan emphasizes that this study challenges the common belief that weight loss naturally leads to increased physical activity. Instead, it highlights the need for targeted interventions that encourage physical activity alongside medication for obesity. The findings underscore the importance of exercise as a non-negotiable component of treatment for individuals taking GLP-1 receptor agonists.
This research is significant as it is the first large-scale study to analyze data from wearable fitness trackers among adults taking GLP-1 receptor agonists. By understanding the impact of these medications on physical activity, healthcare professionals can better support patients in managing their weight loss journey and overall health.
In my opinion, this study serves as a wake-up call for the medical community. It highlights the potential unintended consequences of relying solely on medication for weight loss. While GLP-1 receptor agonists can be effective, they should not replace the importance of physical activity. Healthcare providers should prioritize educating patients about the benefits of exercise and incorporating it into the treatment plan to ensure long-term success and well-being.
